of operations through the February 28, 2007 sale date. The amounts
reported in TT reflect sales of TT products until the completion of
the sale of the TT business, as well as revenues associated with the
manufacturing, distribution and other services provided by the
company to the buyer post-divestiture.
BAXTER INTERNATIONAL INC.
Key Product Line Sales at Actual and Constant Foreign Exchange Rates
Periods Ending September 30, 2007 and 2006
(unaudited)
($ in millions)
% Growth % Growth
@ @
Q3 Q3 Actual Constant
2007 2006(1) Rates Rates
------------------------------------------------------------------------
BioScience
Recombinants (2) $432 $389 11% 8%
Plasma Proteins (3) 246 214 15% 10%
Antibody Therapy 245 196 25% 23%
Regenerative Medicine (4) 82 72 14% 11%
Other (5) 94 96 (2%) (5%)
------------------------------------------------------------------------
Total BioScience (6) $1,099 $967 14% 10%
------------------------------------------------------------------------
Medication Delivery
IV Therapies (7) $346 $317 9% 3%
Global Injectables (8) 372 350 6% 3%
Infusion Systems 207 197 5%
'/>"/>
| SOURCE Baxter International Inc. Copyright©2007 PR Newswire. All rights reserved |